Inozyme Pharma (INZY) Reiterated at Buy by Needham & Company with $23 Price Target, INZ-701 Data is Encouraging and "Near Best-Case"
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $23.00 price target on Inozyme Pharma Inc. (NASDAQ: INZY) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
